Although we observed no significant association between serum CCL4 and OS, we observed higher CCL4 levels in patients with a good treatment response (p < 0.01), those with no adverse features, and found a negative association with serosal invasion and pathologic tumor stage, implicating CCL4 as a marker of favorable anti-tumor immune responses in EAC. Here, CCL4 is linked to neoplasm.